PubMed:19319147 JSONTXT

{"project":"LitCoin-sentences","denotations":[{"id":"T1","span":{"begin":0,"end":125},"obj":"Sentence"},{"id":"T2","span":{"begin":126,"end":206},"obj":"Sentence"},{"id":"T3","span":{"begin":207,"end":264},"obj":"Sentence"},{"id":"T4","span":{"begin":265,"end":428},"obj":"Sentence"},{"id":"T5","span":{"begin":429,"end":566},"obj":"Sentence"},{"id":"T6","span":{"begin":567,"end":673},"obj":"Sentence"},{"id":"T7","span":{"begin":674,"end":782},"obj":"Sentence"},{"id":"T8","span":{"begin":783,"end":895},"obj":"Sentence"},{"id":"T9","span":{"begin":896,"end":1019},"obj":"Sentence"},{"id":"T10","span":{"begin":1020,"end":1168},"obj":"Sentence"},{"id":"T11","span":{"begin":1169,"end":1251},"obj":"Sentence"},{"id":"T12","span":{"begin":1252,"end":1322},"obj":"Sentence"},{"id":"T13","span":{"begin":1323,"end":1458},"obj":"Sentence"},{"id":"T14","span":{"begin":1459,"end":1563},"obj":"Sentence"}],"text":"Rapid reversal of anticoagulation reduces hemorrhage volume in a mouse model of warfarin-associated intracerebral hemorrhage.\nWarfarin-associated intracerebral hemorrhage (W-ICH) is a severe type of stroke. There is no consensus on the optimal treatment for W-ICH. Using a mouse model, we tested whether the rapid reversal of anticoagulation using human prothrombin complex concentrate (PCC) can reduce hemorrhagic blood volume. Male CD-1 mice were treated with warfarin (2 mg/kg over 24 h), resulting in a mean (+/-s.d.) International Normalized Ratio of 3.5+/-0.9. First, we showed that an intravenous administration of human PCC rapidly reversed anticoagulation in mice. Second, a stereotactic injection of collagenase was administered to induce hemorrhage in the right striatum. Forty-five minutes later, the animals were randomly treated with PCC (100 U/kg) or saline i.v. (n=12 per group). Twenty-four hours after hemorrhage induction, hemorrhagic blood volume was quantified using a photometric hemoglobin assay. The mean hemorrhagic blood volume was reduced in PCC-treated animals (6.5+/-3.1 microL) compared with saline controls (15.3+/-11.2 microL, P=0.015). In the saline group, 45% of the mice developed large hematomas (i.e., \u003e15 microL). In contrast, such extensive lesions were never found in the PCC group. We provide experimental data suggesting PCC to be an effective acute treatment for W-ICH in terms of reducing hemorrhagic blood volume. Future studies are needed to assess the therapeutic potential emerging from our finding for human W-ICH."}

{"project":"LitCoin-entities-OrganismTaxon-PD","denotations":[{"id":"T1","span":{"begin":65,"end":70},"obj":"OrganismTaxon"},{"id":"T3","span":{"begin":273,"end":278},"obj":"OrganismTaxon"},{"id":"T5","span":{"begin":348,"end":353},"obj":"OrganismTaxon"},{"id":"T6","span":{"begin":439,"end":443},"obj":"OrganismTaxon"},{"id":"T8","span":{"begin":622,"end":627},"obj":"OrganismTaxon"},{"id":"T9","span":{"begin":668,"end":672},"obj":"OrganismTaxon"},{"id":"T11","span":{"begin":1201,"end":1205},"obj":"OrganismTaxon"},{"id":"T13","span":{"begin":1551,"end":1556},"obj":"OrganismTaxon"}],"attributes":[{"id":"A13","pred":"db_id","subj":"T13","obj":"NCBItxid:9606"},{"id":"A11","pred":"db_id","subj":"T11","obj":"NCBItxid:10095"},{"id":"A12","pred":"db_id","subj":"T11","obj":"NCBItxid:10088"},{"id":"A3","pred":"db_id","subj":"T3","obj":"NCBItxid:10090"},{"id":"A4","pred":"db_id","subj":"T3","obj":"NCBItxid:10088"},{"id":"A6","pred":"db_id","subj":"T6","obj":"NCBItxid:10095"},{"id":"A7","pred":"db_id","subj":"T6","obj":"NCBItxid:10088"},{"id":"A9","pred":"db_id","subj":"T9","obj":"NCBItxid:10095"},{"id":"A10","pred":"db_id","subj":"T9","obj":"NCBItxid:10088"},{"id":"A1","pred":"db_id","subj":"T1","obj":"NCBItxid:10090"},{"id":"A2","pred":"db_id","subj":"T1","obj":"NCBItxid:10088"},{"id":"A5","pred":"db_id","subj":"T5","obj":"NCBItxid:9606"},{"id":"A8","pred":"db_id","subj":"T8","obj":"NCBItxid:9606"}],"text":"Rapid reversal of anticoagulation reduces hemorrhage volume in a mouse model of warfarin-associated intracerebral hemorrhage.\nWarfarin-associated intracerebral hemorrhage (W-ICH) is a severe type of stroke. There is no consensus on the optimal treatment for W-ICH. Using a mouse model, we tested whether the rapid reversal of anticoagulation using human prothrombin complex concentrate (PCC) can reduce hemorrhagic blood volume. Male CD-1 mice were treated with warfarin (2 mg/kg over 24 h), resulting in a mean (+/-s.d.) International Normalized Ratio of 3.5+/-0.9. First, we showed that an intravenous administration of human PCC rapidly reversed anticoagulation in mice. Second, a stereotactic injection of collagenase was administered to induce hemorrhage in the right striatum. Forty-five minutes later, the animals were randomly treated with PCC (100 U/kg) or saline i.v. (n=12 per group). Twenty-four hours after hemorrhage induction, hemorrhagic blood volume was quantified using a photometric hemoglobin assay. The mean hemorrhagic blood volume was reduced in PCC-treated animals (6.5+/-3.1 microL) compared with saline controls (15.3+/-11.2 microL, P=0.015). In the saline group, 45% of the mice developed large hematomas (i.e., \u003e15 microL). In contrast, such extensive lesions were never found in the PCC group. We provide experimental data suggesting PCC to be an effective acute treatment for W-ICH in terms of reducing hemorrhagic blood volume. Future studies are needed to assess the therapeutic potential emerging from our finding for human W-ICH."}

{"project":"LitCoin-entities","denotations":[{"id":"5912","span":{"begin":42,"end":52},"obj":"DiseaseOrPhenotypicFeature"},{"id":"5913","span":{"begin":65,"end":70},"obj":"OrganismTaxon"},{"id":"5914","span":{"begin":80,"end":88},"obj":"ChemicalEntity"},{"id":"5915","span":{"begin":100,"end":124},"obj":"DiseaseOrPhenotypicFeature"},{"id":"5916","span":{"begin":126,"end":134},"obj":"ChemicalEntity"},{"id":"5917","span":{"begin":146,"end":170},"obj":"DiseaseOrPhenotypicFeature"},{"id":"5918","span":{"begin":172,"end":173},"obj":"ChemicalEntity"},{"id":"5919","span":{"begin":174,"end":177},"obj":"DiseaseOrPhenotypicFeature"},{"id":"5920","span":{"begin":199,"end":205},"obj":"DiseaseOrPhenotypicFeature"},{"id":"5921","span":{"begin":258,"end":259},"obj":"ChemicalEntity"},{"id":"5922","span":{"begin":260,"end":263},"obj":"DiseaseOrPhenotypicFeature"},{"id":"5923","span":{"begin":273,"end":278},"obj":"OrganismTaxon"},{"id":"5924","span":{"begin":348,"end":353},"obj":"OrganismTaxon"},{"id":"5925","span":{"begin":354,"end":385},"obj":"ChemicalEntity"},{"id":"5926","span":{"begin":387,"end":390},"obj":"ChemicalEntity"},{"id":"5927","span":{"begin":439,"end":443},"obj":"OrganismTaxon"},{"id":"5928","span":{"begin":462,"end":470},"obj":"ChemicalEntity"},{"id":"5929","span":{"begin":622,"end":627},"obj":"OrganismTaxon"},{"id":"5930","span":{"begin":628,"end":631},"obj":"ChemicalEntity"},{"id":"5931","span":{"begin":668,"end":672},"obj":"OrganismTaxon"},{"id":"5932","span":{"begin":710,"end":721},"obj":"ChemicalEntity"},{"id":"5933","span":{"begin":749,"end":759},"obj":"DiseaseOrPhenotypicFeature"},{"id":"5934","span":{"begin":848,"end":851},"obj":"ChemicalEntity"},{"id":"5935","span":{"begin":920,"end":930},"obj":"DiseaseOrPhenotypicFeature"},{"id":"5936","span":{"begin":1069,"end":1072},"obj":"ChemicalEntity"},{"id":"5937","span":{"begin":1201,"end":1205},"obj":"OrganismTaxon"},{"id":"5938","span":{"begin":1222,"end":1231},"obj":"DiseaseOrPhenotypicFeature"},{"id":"5939","span":{"begin":1312,"end":1315},"obj":"ChemicalEntity"},{"id":"5940","span":{"begin":1363,"end":1366},"obj":"ChemicalEntity"},{"id":"5941","span":{"begin":1406,"end":1407},"obj":"ChemicalEntity"},{"id":"5942","span":{"begin":1408,"end":1411},"obj":"DiseaseOrPhenotypicFeature"},{"id":"5943","span":{"begin":1551,"end":1556},"obj":"OrganismTaxon"},{"id":"5944","span":{"begin":1557,"end":1558},"obj":"ChemicalEntity"},{"id":"5945","span":{"begin":1559,"end":1562},"obj":"DiseaseOrPhenotypicFeature"}],"attributes":[{"id":"A1","pred":"db_id","subj":"5912","obj":"MESH:D006470"},{"id":"A2","pred":"db_id","subj":"5913","obj":"NCBITaxon:10090"},{"id":"A3","pred":"db_id","subj":"5914","obj":"MESH:D014859"},{"id":"A4","pred":"db_id","subj":"5915","obj":"MESH:D002543"},{"id":"A5","pred":"db_id","subj":"5916","obj":"MESH:D014859"},{"id":"A6","pred":"db_id","subj":"5917","obj":"MESH:D002543"},{"id":"A7","pred":"db_id","subj":"5918","obj":"MESH:D014859"},{"id":"A8","pred":"db_id","subj":"5919","obj":"MESH:D002543"},{"id":"A9","pred":"db_id","subj":"5920","obj":"MESH:D020521"},{"id":"A10","pred":"db_id","subj":"5921","obj":"MESH:D014859"},{"id":"A11","pred":"db_id","subj":"5922","obj":"MESH:D002543"},{"id":"A12","pred":"db_id","subj":"5923","obj":"NCBITaxon:10090"},{"id":"A13","pred":"db_id","subj":"5924","obj":"NCBITaxon:9606"},{"id":"A14","pred":"db_id","subj":"5925","obj":"MESH:C025667"},{"id":"A15","pred":"db_id","subj":"5926","obj":"MESH:C025667"},{"id":"A16","pred":"db_id","subj":"5927","obj":"NCBITaxon:10090"},{"id":"A17","pred":"db_id","subj":"5928","obj":"MESH:D014859"},{"id":"A18","pred":"db_id","subj":"5929","obj":"NCBITaxon:9606"},{"id":"A19","pred":"db_id","subj":"5930","obj":"MESH:C025667"},{"id":"A20","pred":"db_id","subj":"5931","obj":"NCBITaxon:10090"},{"id":"A21","pred":"db_id","subj":"5932","obj":"MESH:D017364"},{"id":"A22","pred":"db_id","subj":"5933","obj":"MESH:D006470"},{"id":"A23","pred":"db_id","subj":"5934","obj":"MESH:C025667"},{"id":"A24","pred":"db_id","subj":"5935","obj":"MESH:D006470"},{"id":"A25","pred":"db_id","subj":"5936","obj":"MESH:C025667"},{"id":"A26","pred":"db_id","subj":"5937","obj":"NCBITaxon:10090"},{"id":"A27","pred":"db_id","subj":"5938","obj":"MESH:D006406"},{"id":"A28","pred":"db_id","subj":"5939","obj":"MESH:C025667"},{"id":"A29","pred":"db_id","subj":"5940","obj":"MESH:C025667"},{"id":"A30","pred":"db_id","subj":"5941","obj":"MESH:D014859"},{"id":"A31","pred":"db_id","subj":"5942","obj":"MESH:D002543"},{"id":"A32","pred":"db_id","subj":"5943","obj":"NCBITaxon:9606"},{"id":"A33","pred":"db_id","subj":"5944","obj":"MESH:D014859"},{"id":"A34","pred":"db_id","subj":"5945","obj":"MESH:D002543"}],"namespaces":[{"prefix":"_base","uri":"https://w3id.org/biolink/vocab/"},{"prefix":"MESH","uri":"http://id.nlm.nih.gov/mesh/"},{"prefix":"NCBITaxon","uri":"https://www.ncbi.nlm.nih.gov/Taxonomy/Browser/wwwtax.cgi?id="},{"prefix":"NCBIGene","uri":"https://www.ncbi.nlm.nih.gov/gene/"},{"prefix":"OMIM","uri":"https://www.omim.org/entry/"},{"prefix":"DBSNP","uri":"https://www.ncbi.nlm.nih.gov/snp/"}],"text":"Rapid reversal of anticoagulation reduces hemorrhage volume in a mouse model of warfarin-associated intracerebral hemorrhage.\nWarfarin-associated intracerebral hemorrhage (W-ICH) is a severe type of stroke. There is no consensus on the optimal treatment for W-ICH. Using a mouse model, we tested whether the rapid reversal of anticoagulation using human prothrombin complex concentrate (PCC) can reduce hemorrhagic blood volume. Male CD-1 mice were treated with warfarin (2 mg/kg over 24 h), resulting in a mean (+/-s.d.) International Normalized Ratio of 3.5+/-0.9. First, we showed that an intravenous administration of human PCC rapidly reversed anticoagulation in mice. Second, a stereotactic injection of collagenase was administered to induce hemorrhage in the right striatum. Forty-five minutes later, the animals were randomly treated with PCC (100 U/kg) or saline i.v. (n=12 per group). Twenty-four hours after hemorrhage induction, hemorrhagic blood volume was quantified using a photometric hemoglobin assay. The mean hemorrhagic blood volume was reduced in PCC-treated animals (6.5+/-3.1 microL) compared with saline controls (15.3+/-11.2 microL, P=0.015). In the saline group, 45% of the mice developed large hematomas (i.e., \u003e15 microL). In contrast, such extensive lesions were never found in the PCC group. We provide experimental data suggesting PCC to be an effective acute treatment for W-ICH in terms of reducing hemorrhagic blood volume. Future studies are needed to assess the therapeutic potential emerging from our finding for human W-ICH."}

{"project":"LitCoin_Mondo","denotations":[{"id":"T1","span":{"begin":100,"end":124},"obj":"DiseaseOrPhenotypicFeature"},{"id":"T2","span":{"begin":146,"end":170},"obj":"DiseaseOrPhenotypicFeature"}],"attributes":[{"id":"A1","pred":"mondo_id","subj":"T1","obj":"0013792"},{"id":"A2","pred":"mondo_id","subj":"T2","obj":"0013792"}],"text":"Rapid reversal of anticoagulation reduces hemorrhage volume in a mouse model of warfarin-associated intracerebral hemorrhage.\nWarfarin-associated intracerebral hemorrhage (W-ICH) is a severe type of stroke. There is no consensus on the optimal treatment for W-ICH. Using a mouse model, we tested whether the rapid reversal of anticoagulation using human prothrombin complex concentrate (PCC) can reduce hemorrhagic blood volume. Male CD-1 mice were treated with warfarin (2 mg/kg over 24 h), resulting in a mean (+/-s.d.) International Normalized Ratio of 3.5+/-0.9. First, we showed that an intravenous administration of human PCC rapidly reversed anticoagulation in mice. Second, a stereotactic injection of collagenase was administered to induce hemorrhage in the right striatum. Forty-five minutes later, the animals were randomly treated with PCC (100 U/kg) or saline i.v. (n=12 per group). Twenty-four hours after hemorrhage induction, hemorrhagic blood volume was quantified using a photometric hemoglobin assay. The mean hemorrhagic blood volume was reduced in PCC-treated animals (6.5+/-3.1 microL) compared with saline controls (15.3+/-11.2 microL, P=0.015). In the saline group, 45% of the mice developed large hematomas (i.e., \u003e15 microL). In contrast, such extensive lesions were never found in the PCC group. We provide experimental data suggesting PCC to be an effective acute treatment for W-ICH in terms of reducing hemorrhagic blood volume. Future studies are needed to assess the therapeutic potential emerging from our finding for human W-ICH."}

{"project":"LitCoin-GeneOrGeneProduct-v0","denotations":[{"id":"T1","span":{"begin":34,"end":41},"obj":"GeneOrGeneProduct"},{"id":"T2","span":{"begin":60,"end":64},"obj":"GeneOrGeneProduct"},{"id":"T3","span":{"begin":172,"end":177},"obj":"GeneOrGeneProduct"},{"id":"T4","span":{"begin":258,"end":263},"obj":"GeneOrGeneProduct"},{"id":"T5","span":{"begin":289,"end":295},"obj":"GeneOrGeneProduct"},{"id":"T6","span":{"begin":354,"end":365},"obj":"GeneOrGeneProduct"},{"id":"T7","span":{"begin":396,"end":402},"obj":"GeneOrGeneProduct"},{"id":"T8","span":{"begin":429,"end":433},"obj":"GeneOrGeneProduct"},{"id":"T9","span":{"begin":434,"end":438},"obj":"GeneOrGeneProduct"},{"id":"T10","span":{"begin":439,"end":443},"obj":"GeneOrGeneProduct"},{"id":"T11","span":{"begin":474,"end":476},"obj":"GeneOrGeneProduct"},{"id":"T12","span":{"begin":502,"end":506},"obj":"GeneOrGeneProduct"},{"id":"T13","span":{"begin":668,"end":672},"obj":"GeneOrGeneProduct"},{"id":"T14","span":{"begin":710,"end":721},"obj":"GeneOrGeneProduct"},{"id":"T15","span":{"begin":742,"end":748},"obj":"GeneOrGeneProduct"},{"id":"T16","span":{"begin":767,"end":772},"obj":"GeneOrGeneProduct"},{"id":"T17","span":{"begin":794,"end":801},"obj":"GeneOrGeneProduct"},{"id":"T18","span":{"begin":802,"end":807},"obj":"GeneOrGeneProduct"},{"id":"T19","span":{"begin":879,"end":883},"obj":"GeneOrGeneProduct"},{"id":"T20","span":{"begin":884,"end":887},"obj":"GeneOrGeneProduct"},{"id":"T21","span":{"begin":896,"end":907},"obj":"GeneOrGeneProduct"},{"id":"T22","span":{"begin":1002,"end":1012},"obj":"GeneOrGeneProduct"},{"id":"T23","span":{"begin":1058,"end":1065},"obj":"GeneOrGeneProduct"},{"id":"T24","span":{"begin":1201,"end":1205},"obj":"GeneOrGeneProduct"},{"id":"T25","span":{"begin":1216,"end":1221},"obj":"GeneOrGeneProduct"},{"id":"T26","span":{"begin":1255,"end":1263},"obj":"GeneOrGeneProduct"},{"id":"T27","span":{"begin":1270,"end":1279},"obj":"GeneOrGeneProduct"},{"id":"T28","span":{"begin":1280,"end":1287},"obj":"GeneOrGeneProduct"},{"id":"T29","span":{"begin":1406,"end":1411},"obj":"GeneOrGeneProduct"},{"id":"T30","span":{"begin":1415,"end":1420},"obj":"GeneOrGeneProduct"},{"id":"T31","span":{"begin":1424,"end":1432},"obj":"GeneOrGeneProduct"},{"id":"T32","span":{"begin":1539,"end":1546},"obj":"GeneOrGeneProduct"},{"id":"T33","span":{"begin":1557,"end":1562},"obj":"GeneOrGeneProduct"}],"text":"Rapid reversal of anticoagulation reduces hemorrhage volume in a mouse model of warfarin-associated intracerebral hemorrhage.\nWarfarin-associated intracerebral hemorrhage (W-ICH) is a severe type of stroke. There is no consensus on the optimal treatment for W-ICH. Using a mouse model, we tested whether the rapid reversal of anticoagulation using human prothrombin complex concentrate (PCC) can reduce hemorrhagic blood volume. Male CD-1 mice were treated with warfarin (2 mg/kg over 24 h), resulting in a mean (+/-s.d.) International Normalized Ratio of 3.5+/-0.9. First, we showed that an intravenous administration of human PCC rapidly reversed anticoagulation in mice. Second, a stereotactic injection of collagenase was administered to induce hemorrhage in the right striatum. Forty-five minutes later, the animals were randomly treated with PCC (100 U/kg) or saline i.v. (n=12 per group). Twenty-four hours after hemorrhage induction, hemorrhagic blood volume was quantified using a photometric hemoglobin assay. The mean hemorrhagic blood volume was reduced in PCC-treated animals (6.5+/-3.1 microL) compared with saline controls (15.3+/-11.2 microL, P=0.015). In the saline group, 45% of the mice developed large hematomas (i.e., \u003e15 microL). In contrast, such extensive lesions were never found in the PCC group. We provide experimental data suggesting PCC to be an effective acute treatment for W-ICH in terms of reducing hemorrhagic blood volume. Future studies are needed to assess the therapeutic potential emerging from our finding for human W-ICH."}

{"project":"LitCoin-GeneOrGeneProduct-v2","denotations":[{"id":"T1","span":{"begin":172,"end":177},"obj":"GeneOrGeneProduct"},{"id":"T2","span":{"begin":258,"end":263},"obj":"GeneOrGeneProduct"},{"id":"T3","span":{"begin":354,"end":365},"obj":"GeneOrGeneProduct"},{"id":"T4","span":{"begin":710,"end":721},"obj":"GeneOrGeneProduct"},{"id":"T5","span":{"begin":896,"end":907},"obj":"GeneOrGeneProduct"},{"id":"T6","span":{"begin":1002,"end":1012},"obj":"GeneOrGeneProduct"},{"id":"T7","span":{"begin":1058,"end":1065},"obj":"GeneOrGeneProduct"},{"id":"T8","span":{"begin":1216,"end":1221},"obj":"GeneOrGeneProduct"},{"id":"T9","span":{"begin":1280,"end":1287},"obj":"GeneOrGeneProduct"},{"id":"T10","span":{"begin":1406,"end":1411},"obj":"GeneOrGeneProduct"},{"id":"T11","span":{"begin":1557,"end":1562},"obj":"GeneOrGeneProduct"}],"text":"Rapid reversal of anticoagulation reduces hemorrhage volume in a mouse model of warfarin-associated intracerebral hemorrhage.\nWarfarin-associated intracerebral hemorrhage (W-ICH) is a severe type of stroke. There is no consensus on the optimal treatment for W-ICH. Using a mouse model, we tested whether the rapid reversal of anticoagulation using human prothrombin complex concentrate (PCC) can reduce hemorrhagic blood volume. Male CD-1 mice were treated with warfarin (2 mg/kg over 24 h), resulting in a mean (+/-s.d.) International Normalized Ratio of 3.5+/-0.9. First, we showed that an intravenous administration of human PCC rapidly reversed anticoagulation in mice. Second, a stereotactic injection of collagenase was administered to induce hemorrhage in the right striatum. Forty-five minutes later, the animals were randomly treated with PCC (100 U/kg) or saline i.v. (n=12 per group). Twenty-four hours after hemorrhage induction, hemorrhagic blood volume was quantified using a photometric hemoglobin assay. The mean hemorrhagic blood volume was reduced in PCC-treated animals (6.5+/-3.1 microL) compared with saline controls (15.3+/-11.2 microL, P=0.015). In the saline group, 45% of the mice developed large hematomas (i.e., \u003e15 microL). In contrast, such extensive lesions were never found in the PCC group. We provide experimental data suggesting PCC to be an effective acute treatment for W-ICH in terms of reducing hemorrhagic blood volume. Future studies are needed to assess the therapeutic potential emerging from our finding for human W-ICH."}

{"project":"LitCoin-Disease-MeSH","denotations":[{"id":"T1","span":{"begin":42,"end":52},"obj":"DiseaseOrPhenotypicFeature"},{"id":"T2","span":{"begin":100,"end":124},"obj":"DiseaseOrPhenotypicFeature"},{"id":"T3","span":{"begin":146,"end":170},"obj":"DiseaseOrPhenotypicFeature"},{"id":"T4","span":{"begin":199,"end":205},"obj":"DiseaseOrPhenotypicFeature"},{"id":"T5","span":{"begin":403,"end":414},"obj":"DiseaseOrPhenotypicFeature"},{"id":"T6","span":{"begin":749,"end":759},"obj":"DiseaseOrPhenotypicFeature"},{"id":"T7","span":{"begin":920,"end":930},"obj":"DiseaseOrPhenotypicFeature"},{"id":"T8","span":{"begin":942,"end":953},"obj":"DiseaseOrPhenotypicFeature"},{"id":"T9","span":{"begin":1029,"end":1040},"obj":"DiseaseOrPhenotypicFeature"},{"id":"T10","span":{"begin":1222,"end":1231},"obj":"DiseaseOrPhenotypicFeature"},{"id":"T11","span":{"begin":1433,"end":1444},"obj":"DiseaseOrPhenotypicFeature"}],"attributes":[{"id":"A8","pred":"originalLabel","subj":"T8","obj":"D006470"},{"id":"A2","pred":"originalLabel","subj":"T2","obj":"D002543"},{"id":"A10","pred":"originalLabel","subj":"T10","obj":"D006406"},{"id":"A11","pred":"originalLabel","subj":"T11","obj":"D006470"},{"id":"A3","pred":"originalLabel","subj":"T3","obj":"D002543"},{"id":"A1","pred":"originalLabel","subj":"T1","obj":"D006470"},{"id":"A4","pred":"originalLabel","subj":"T4","obj":"D020521"},{"id":"A9","pred":"originalLabel","subj":"T9","obj":"D006470"},{"id":"A7","pred":"originalLabel","subj":"T7","obj":"D006470"},{"id":"A5","pred":"originalLabel","subj":"T5","obj":"D006470"},{"id":"A6","pred":"originalLabel","subj":"T6","obj":"D006470"}],"text":"Rapid reversal of anticoagulation reduces hemorrhage volume in a mouse model of warfarin-associated intracerebral hemorrhage.\nWarfarin-associated intracerebral hemorrhage (W-ICH) is a severe type of stroke. There is no consensus on the optimal treatment for W-ICH. Using a mouse model, we tested whether the rapid reversal of anticoagulation using human prothrombin complex concentrate (PCC) can reduce hemorrhagic blood volume. Male CD-1 mice were treated with warfarin (2 mg/kg over 24 h), resulting in a mean (+/-s.d.) International Normalized Ratio of 3.5+/-0.9. First, we showed that an intravenous administration of human PCC rapidly reversed anticoagulation in mice. Second, a stereotactic injection of collagenase was administered to induce hemorrhage in the right striatum. Forty-five minutes later, the animals were randomly treated with PCC (100 U/kg) or saline i.v. (n=12 per group). Twenty-four hours after hemorrhage induction, hemorrhagic blood volume was quantified using a photometric hemoglobin assay. The mean hemorrhagic blood volume was reduced in PCC-treated animals (6.5+/-3.1 microL) compared with saline controls (15.3+/-11.2 microL, P=0.015). In the saline group, 45% of the mice developed large hematomas (i.e., \u003e15 microL). In contrast, such extensive lesions were never found in the PCC group. We provide experimental data suggesting PCC to be an effective acute treatment for W-ICH in terms of reducing hemorrhagic blood volume. Future studies are needed to assess the therapeutic potential emerging from our finding for human W-ICH."}

{"project":"LitCoin-GeneOrGeneProduct-v3","denotations":[{"id":"T1","span":{"begin":354,"end":365},"obj":"GeneOrGeneProduct"},{"id":"T2","span":{"begin":1002,"end":1012},"obj":"GeneOrGeneProduct"}],"text":"Rapid reversal of anticoagulation reduces hemorrhage volume in a mouse model of warfarin-associated intracerebral hemorrhage.\nWarfarin-associated intracerebral hemorrhage (W-ICH) is a severe type of stroke. There is no consensus on the optimal treatment for W-ICH. Using a mouse model, we tested whether the rapid reversal of anticoagulation using human prothrombin complex concentrate (PCC) can reduce hemorrhagic blood volume. Male CD-1 mice were treated with warfarin (2 mg/kg over 24 h), resulting in a mean (+/-s.d.) International Normalized Ratio of 3.5+/-0.9. First, we showed that an intravenous administration of human PCC rapidly reversed anticoagulation in mice. Second, a stereotactic injection of collagenase was administered to induce hemorrhage in the right striatum. Forty-five minutes later, the animals were randomly treated with PCC (100 U/kg) or saline i.v. (n=12 per group). Twenty-four hours after hemorrhage induction, hemorrhagic blood volume was quantified using a photometric hemoglobin assay. The mean hemorrhagic blood volume was reduced in PCC-treated animals (6.5+/-3.1 microL) compared with saline controls (15.3+/-11.2 microL, P=0.015). In the saline group, 45% of the mice developed large hematomas (i.e., \u003e15 microL). In contrast, such extensive lesions were never found in the PCC group. We provide experimental data suggesting PCC to be an effective acute treatment for W-ICH in terms of reducing hemorrhagic blood volume. Future studies are needed to assess the therapeutic potential emerging from our finding for human W-ICH."}

{"project":"LitCoin_Mondo_095","denotations":[{"id":"T1","span":{"begin":100,"end":124},"obj":"DiseaseOrPhenotypicFeature"},{"id":"T2","span":{"begin":146,"end":170},"obj":"DiseaseOrPhenotypicFeature"},{"id":"T3","span":{"begin":199,"end":205},"obj":"DiseaseOrPhenotypicFeature"},{"id":"T4","span":{"begin":387,"end":390},"obj":"DiseaseOrPhenotypicFeature"},{"id":"T6","span":{"begin":392,"end":395},"obj":"DiseaseOrPhenotypicFeature"},{"id":"T7","span":{"begin":434,"end":436},"obj":"DiseaseOrPhenotypicFeature"},{"id":"T8","span":{"begin":628,"end":631},"obj":"DiseaseOrPhenotypicFeature"},{"id":"T10","span":{"begin":848,"end":851},"obj":"DiseaseOrPhenotypicFeature"},{"id":"T12","span":{"begin":1069,"end":1072},"obj":"DiseaseOrPhenotypicFeature"},{"id":"T14","span":{"begin":1312,"end":1315},"obj":"DiseaseOrPhenotypicFeature"},{"id":"T16","span":{"begin":1363,"end":1366},"obj":"DiseaseOrPhenotypicFeature"}],"attributes":[{"id":"A3","pred":"mondo_id","subj":"T3","obj":"0005098"},{"id":"A8","pred":"mondo_id","subj":"T8","obj":"0022673"},{"id":"A9","pred":"mondo_id","subj":"T8","obj":"0004974"},{"id":"A7","pred":"mondo_id","subj":"T7","obj":"0016063"},{"id":"A2","pred":"mondo_id","subj":"T2","obj":"0013792"},{"id":"A10","pred":"mondo_id","subj":"T10","obj":"0022673"},{"id":"A11","pred":"mondo_id","subj":"T10","obj":"0004974"},{"id":"A6","pred":"mondo_id","subj":"T6","obj":"0012833"},{"id":"A12","pred":"mondo_id","subj":"T12","obj":"0022673"},{"id":"A13","pred":"mondo_id","subj":"T12","obj":"0004974"},{"id":"A4","pred":"mondo_id","subj":"T4","obj":"0022673"},{"id":"A5","pred":"mondo_id","subj":"T4","obj":"0004974"},{"id":"A14","pred":"mondo_id","subj":"T14","obj":"0022673"},{"id":"A15","pred":"mondo_id","subj":"T14","obj":"0004974"},{"id":"A1","pred":"mondo_id","subj":"T1","obj":"0013792"},{"id":"A16","pred":"mondo_id","subj":"T16","obj":"0022673"},{"id":"A17","pred":"mondo_id","subj":"T16","obj":"0004974"}],"text":"Rapid reversal of anticoagulation reduces hemorrhage volume in a mouse model of warfarin-associated intracerebral hemorrhage.\nWarfarin-associated intracerebral hemorrhage (W-ICH) is a severe type of stroke. There is no consensus on the optimal treatment for W-ICH. Using a mouse model, we tested whether the rapid reversal of anticoagulation using human prothrombin complex concentrate (PCC) can reduce hemorrhagic blood volume. Male CD-1 mice were treated with warfarin (2 mg/kg over 24 h), resulting in a mean (+/-s.d.) International Normalized Ratio of 3.5+/-0.9. First, we showed that an intravenous administration of human PCC rapidly reversed anticoagulation in mice. Second, a stereotactic injection of collagenase was administered to induce hemorrhage in the right striatum. Forty-five minutes later, the animals were randomly treated with PCC (100 U/kg) or saline i.v. (n=12 per group). Twenty-four hours after hemorrhage induction, hemorrhagic blood volume was quantified using a photometric hemoglobin assay. The mean hemorrhagic blood volume was reduced in PCC-treated animals (6.5+/-3.1 microL) compared with saline controls (15.3+/-11.2 microL, P=0.015). In the saline group, 45% of the mice developed large hematomas (i.e., \u003e15 microL). In contrast, such extensive lesions were never found in the PCC group. We provide experimental data suggesting PCC to be an effective acute treatment for W-ICH in terms of reducing hemorrhagic blood volume. Future studies are needed to assess the therapeutic potential emerging from our finding for human W-ICH."}

{"project":"LitCoin-MeSH-Disease-2","denotations":[{"id":"T1","span":{"begin":42,"end":52},"obj":"DiseaseOrPhenotypicFeature"},{"id":"T3","span":{"begin":100,"end":124},"obj":"DiseaseOrPhenotypicFeature"},{"id":"T4","span":{"begin":146,"end":170},"obj":"DiseaseOrPhenotypicFeature"},{"id":"T5","span":{"begin":174,"end":177},"obj":"DiseaseOrPhenotypicFeature"},{"id":"T6","span":{"begin":199,"end":205},"obj":"DiseaseOrPhenotypicFeature"},{"id":"T8","span":{"begin":260,"end":263},"obj":"DiseaseOrPhenotypicFeature"},{"id":"T9","span":{"begin":749,"end":759},"obj":"DiseaseOrPhenotypicFeature"},{"id":"T11","span":{"begin":920,"end":930},"obj":"DiseaseOrPhenotypicFeature"},{"id":"T13","span":{"begin":1222,"end":1231},"obj":"DiseaseOrPhenotypicFeature"},{"id":"T14","span":{"begin":1408,"end":1411},"obj":"DiseaseOrPhenotypicFeature"},{"id":"T15","span":{"begin":1559,"end":1562},"obj":"DiseaseOrPhenotypicFeature"}],"attributes":[{"id":"A11","pred":"ID:","subj":"T11","obj":"DISEASE"},{"id":"A12","pred":"ID:","subj":"T11","obj":"D006470"},{"id":"A4","pred":"ID:","subj":"T4","obj":"D002543"},{"id":"A3","pred":"ID:","subj":"T3","obj":"D002543"},{"id":"A1","pred":"ID:","subj":"T1","obj":"DISEASE"},{"id":"A2","pred":"ID:","subj":"T1","obj":"D006470"},{"id":"A14","pred":"ID:","subj":"T14","obj":"DISEASE"},{"id":"A8","pred":"ID:","subj":"T8","obj":"DISEASE"},{"id":"A5","pred":"ID:","subj":"T5","obj":"DISEASE"},{"id":"A6","pred":"ID:","subj":"T6","obj":"DISEASE"},{"id":"A7","pred":"ID:","subj":"T6","obj":"D020521"},{"id":"A9","pred":"ID:","subj":"T9","obj":"DISEASE"},{"id":"A10","pred":"ID:","subj":"T9","obj":"D006470"},{"id":"A15","pred":"ID:","subj":"T15","obj":"DISEASE"},{"id":"A13","pred":"ID:","subj":"T13","obj":"D006406"}],"text":"Rapid reversal of anticoagulation reduces hemorrhage volume in a mouse model of warfarin-associated intracerebral hemorrhage.\nWarfarin-associated intracerebral hemorrhage (W-ICH) is a severe type of stroke. There is no consensus on the optimal treatment for W-ICH. Using a mouse model, we tested whether the rapid reversal of anticoagulation using human prothrombin complex concentrate (PCC) can reduce hemorrhagic blood volume. Male CD-1 mice were treated with warfarin (2 mg/kg over 24 h), resulting in a mean (+/-s.d.) International Normalized Ratio of 3.5+/-0.9. First, we showed that an intravenous administration of human PCC rapidly reversed anticoagulation in mice. Second, a stereotactic injection of collagenase was administered to induce hemorrhage in the right striatum. Forty-five minutes later, the animals were randomly treated with PCC (100 U/kg) or saline i.v. (n=12 per group). Twenty-four hours after hemorrhage induction, hemorrhagic blood volume was quantified using a photometric hemoglobin assay. The mean hemorrhagic blood volume was reduced in PCC-treated animals (6.5+/-3.1 microL) compared with saline controls (15.3+/-11.2 microL, P=0.015). In the saline group, 45% of the mice developed large hematomas (i.e., \u003e15 microL). In contrast, such extensive lesions were never found in the PCC group. We provide experimental data suggesting PCC to be an effective acute treatment for W-ICH in terms of reducing hemorrhagic blood volume. Future studies are needed to assess the therapeutic potential emerging from our finding for human W-ICH."}

{"project":"LitCoin-MONDO_bioort2019","denotations":[{"id":"T1","span":{"begin":42,"end":52},"obj":"DiseaseOrPhenotypicFeature"},{"id":"T2","span":{"begin":100,"end":124},"obj":"DiseaseOrPhenotypicFeature"},{"id":"T3","span":{"begin":146,"end":170},"obj":"DiseaseOrPhenotypicFeature"},{"id":"T4","span":{"begin":174,"end":177},"obj":"DiseaseOrPhenotypicFeature"},{"id":"T5","span":{"begin":199,"end":205},"obj":"DiseaseOrPhenotypicFeature"},{"id":"T6","span":{"begin":260,"end":263},"obj":"DiseaseOrPhenotypicFeature"},{"id":"T7","span":{"begin":749,"end":759},"obj":"DiseaseOrPhenotypicFeature"},{"id":"T8","span":{"begin":920,"end":930},"obj":"DiseaseOrPhenotypicFeature"},{"id":"T9","span":{"begin":1222,"end":1231},"obj":"DiseaseOrPhenotypicFeature"},{"id":"T10","span":{"begin":1408,"end":1411},"obj":"DiseaseOrPhenotypicFeature"},{"id":"T11","span":{"begin":1559,"end":1562},"obj":"DiseaseOrPhenotypicFeature"}],"attributes":[{"id":"A2","pred":"#label","subj":"T2","obj":"D002543"},{"id":"A6","pred":"#label","subj":"T6","obj":"DISEASE"},{"id":"A3","pred":"#label","subj":"T3","obj":"D002543"},{"id":"A7","pred":"#label","subj":"T7","obj":"D006470"},{"id":"A9","pred":"#label","subj":"T9","obj":"D006406"},{"id":"A5","pred":"#label","subj":"T5","obj":"D020521"},{"id":"A10","pred":"#label","subj":"T10","obj":"DISEASE"},{"id":"A4","pred":"#label","subj":"T4","obj":"DISEASE"},{"id":"A1","pred":"#label","subj":"T1","obj":"D006470"},{"id":"A8","pred":"#label","subj":"T8","obj":"D006470"},{"id":"A11","pred":"#label","subj":"T11","obj":"DISEASE"}],"text":"Rapid reversal of anticoagulation reduces hemorrhage volume in a mouse model of warfarin-associated intracerebral hemorrhage.\nWarfarin-associated intracerebral hemorrhage (W-ICH) is a severe type of stroke. There is no consensus on the optimal treatment for W-ICH. Using a mouse model, we tested whether the rapid reversal of anticoagulation using human prothrombin complex concentrate (PCC) can reduce hemorrhagic blood volume. Male CD-1 mice were treated with warfarin (2 mg/kg over 24 h), resulting in a mean (+/-s.d.) International Normalized Ratio of 3.5+/-0.9. First, we showed that an intravenous administration of human PCC rapidly reversed anticoagulation in mice. Second, a stereotactic injection of collagenase was administered to induce hemorrhage in the right striatum. Forty-five minutes later, the animals were randomly treated with PCC (100 U/kg) or saline i.v. (n=12 per group). Twenty-four hours after hemorrhage induction, hemorrhagic blood volume was quantified using a photometric hemoglobin assay. The mean hemorrhagic blood volume was reduced in PCC-treated animals (6.5+/-3.1 microL) compared with saline controls (15.3+/-11.2 microL, P=0.015). In the saline group, 45% of the mice developed large hematomas (i.e., \u003e15 microL). In contrast, such extensive lesions were never found in the PCC group. We provide experimental data suggesting PCC to be an effective acute treatment for W-ICH in terms of reducing hemorrhagic blood volume. Future studies are needed to assess the therapeutic potential emerging from our finding for human W-ICH."}

{"project":"LitCoin-NCBITaxon-2","denotations":[{"id":"T1","span":{"begin":65,"end":70},"obj":"OrganismTaxon"},{"id":"T2","span":{"begin":273,"end":278},"obj":"OrganismTaxon"},{"id":"T3","span":{"begin":348,"end":353},"obj":"OrganismTaxon"},{"id":"T4","span":{"begin":439,"end":443},"obj":"OrganismTaxon"},{"id":"T5","span":{"begin":622,"end":627},"obj":"OrganismTaxon"},{"id":"T6","span":{"begin":668,"end":672},"obj":"OrganismTaxon"},{"id":"T7","span":{"begin":1201,"end":1205},"obj":"OrganismTaxon"},{"id":"T8","span":{"begin":1551,"end":1556},"obj":"OrganismTaxon"}],"text":"Rapid reversal of anticoagulation reduces hemorrhage volume in a mouse model of warfarin-associated intracerebral hemorrhage.\nWarfarin-associated intracerebral hemorrhage (W-ICH) is a severe type of stroke. There is no consensus on the optimal treatment for W-ICH. Using a mouse model, we tested whether the rapid reversal of anticoagulation using human prothrombin complex concentrate (PCC) can reduce hemorrhagic blood volume. Male CD-1 mice were treated with warfarin (2 mg/kg over 24 h), resulting in a mean (+/-s.d.) International Normalized Ratio of 3.5+/-0.9. First, we showed that an intravenous administration of human PCC rapidly reversed anticoagulation in mice. Second, a stereotactic injection of collagenase was administered to induce hemorrhage in the right striatum. Forty-five minutes later, the animals were randomly treated with PCC (100 U/kg) or saline i.v. (n=12 per group). Twenty-four hours after hemorrhage induction, hemorrhagic blood volume was quantified using a photometric hemoglobin assay. The mean hemorrhagic blood volume was reduced in PCC-treated animals (6.5+/-3.1 microL) compared with saline controls (15.3+/-11.2 microL, P=0.015). In the saline group, 45% of the mice developed large hematomas (i.e., \u003e15 microL). In contrast, such extensive lesions were never found in the PCC group. We provide experimental data suggesting PCC to be an effective acute treatment for W-ICH in terms of reducing hemorrhagic blood volume. Future studies are needed to assess the therapeutic potential emerging from our finding for human W-ICH."}

{"project":"LitCoin-Chemical-MeSH-CHEBI","denotations":[{"id":"T1","span":{"begin":80,"end":88},"obj":"ChemicalEntity"},{"id":"T3","span":{"begin":126,"end":134},"obj":"ChemicalEntity"},{"id":"T5","span":{"begin":354,"end":365},"obj":"ChemicalEntity"},{"id":"T6","span":{"begin":387,"end":390},"obj":"ChemicalEntity"},{"id":"T7","span":{"begin":462,"end":470},"obj":"ChemicalEntity"},{"id":"T9","span":{"begin":628,"end":631},"obj":"ChemicalEntity"},{"id":"T10","span":{"begin":710,"end":721},"obj":"ChemicalEntity"},{"id":"T12","span":{"begin":848,"end":851},"obj":"ChemicalEntity"},{"id":"T13","span":{"begin":1002,"end":1012},"obj":"ChemicalEntity"},{"id":"T14","span":{"begin":1069,"end":1072},"obj":"ChemicalEntity"},{"id":"T15","span":{"begin":1312,"end":1315},"obj":"ChemicalEntity"},{"id":"T16","span":{"begin":1363,"end":1366},"obj":"ChemicalEntity"}],"attributes":[{"id":"A1","pred":"ID:","subj":"T1","obj":"D014859"},{"id":"A2","pred":"ID:","subj":"T1","obj":"http://purl.obolibrary.org/obo/CHEBI_10033"},{"id":"A3","pred":"ID:","subj":"T3","obj":"D014859"},{"id":"A4","pred":"ID:","subj":"T3","obj":"http://purl.obolibrary.org/obo/CHEBI_10033"},{"id":"A5","pred":"ID:","subj":"T5","obj":"http://purl.obolibrary.org/obo/CHEBI_8583"},{"id":"A6","pred":"ID:","subj":"T6","obj":"ChemicalEntity"},{"id":"A7","pred":"ID:","subj":"T7","obj":"D014859"},{"id":"A8","pred":"ID:","subj":"T7","obj":"http://purl.obolibrary.org/obo/CHEBI_10033"},{"id":"A9","pred":"ID:","subj":"T9","obj":"ChemicalEntity"},{"id":"A10","pred":"ID:","subj":"T10","obj":"D017364"},{"id":"A11","pred":"ID:","subj":"T10","obj":"ChemicalEntity"},{"id":"A12","pred":"ID:","subj":"T12","obj":"ChemicalEntity"},{"id":"A13","pred":"ID:","subj":"T13","obj":"http://purl.obolibrary.org/obo/CHEBI_35143"},{"id":"A14","pred":"ID:","subj":"T14","obj":"ChemicalEntity"},{"id":"A15","pred":"ID:","subj":"T15","obj":"ChemicalEntity"},{"id":"A16","pred":"ID:","subj":"T16","obj":"ChemicalEntity"}],"text":"Rapid reversal of anticoagulation reduces hemorrhage volume in a mouse model of warfarin-associated intracerebral hemorrhage.\nWarfarin-associated intracerebral hemorrhage (W-ICH) is a severe type of stroke. There is no consensus on the optimal treatment for W-ICH. Using a mouse model, we tested whether the rapid reversal of anticoagulation using human prothrombin complex concentrate (PCC) can reduce hemorrhagic blood volume. Male CD-1 mice were treated with warfarin (2 mg/kg over 24 h), resulting in a mean (+/-s.d.) International Normalized Ratio of 3.5+/-0.9. First, we showed that an intravenous administration of human PCC rapidly reversed anticoagulation in mice. Second, a stereotactic injection of collagenase was administered to induce hemorrhage in the right striatum. Forty-five minutes later, the animals were randomly treated with PCC (100 U/kg) or saline i.v. (n=12 per group). Twenty-four hours after hemorrhage induction, hemorrhagic blood volume was quantified using a photometric hemoglobin assay. The mean hemorrhagic blood volume was reduced in PCC-treated animals (6.5+/-3.1 microL) compared with saline controls (15.3+/-11.2 microL, P=0.015). In the saline group, 45% of the mice developed large hematomas (i.e., \u003e15 microL). In contrast, such extensive lesions were never found in the PCC group. We provide experimental data suggesting PCC to be an effective acute treatment for W-ICH in terms of reducing hemorrhagic blood volume. Future studies are needed to assess the therapeutic potential emerging from our finding for human W-ICH."}

{"project":"LitCoin-training-merged","denotations":[{"id":"T16","span":{"begin":1363,"end":1366},"obj":"ChemicalEntity"},{"id":"T15","span":{"begin":1312,"end":1315},"obj":"ChemicalEntity"},{"id":"T14","span":{"begin":1069,"end":1072},"obj":"ChemicalEntity"},{"id":"T13","span":{"begin":1002,"end":1012},"obj":"ChemicalEntity"},{"id":"T12","span":{"begin":848,"end":851},"obj":"ChemicalEntity"},{"id":"T10","span":{"begin":710,"end":721},"obj":"ChemicalEntity"},{"id":"T9","span":{"begin":628,"end":631},"obj":"ChemicalEntity"},{"id":"T7","span":{"begin":462,"end":470},"obj":"ChemicalEntity"},{"id":"T6","span":{"begin":387,"end":390},"obj":"ChemicalEntity"},{"id":"T5","span":{"begin":354,"end":365},"obj":"ChemicalEntity"},{"id":"T3","span":{"begin":126,"end":134},"obj":"ChemicalEntity"},{"id":"T1","span":{"begin":80,"end":88},"obj":"ChemicalEntity"},{"id":"T2","span":{"begin":1002,"end":1012},"obj":"GeneOrGeneProduct"},{"id":"T4882","span":{"begin":354,"end":365},"obj":"GeneOrGeneProduct"},{"id":"T11","span":{"begin":1559,"end":1562},"obj":"DiseaseOrPhenotypicFeature"},{"id":"T24843","span":{"begin":1408,"end":1411},"obj":"DiseaseOrPhenotypicFeature"},{"id":"T64851","span":{"begin":1222,"end":1231},"obj":"DiseaseOrPhenotypicFeature"},{"id":"T8","span":{"begin":920,"end":930},"obj":"DiseaseOrPhenotypicFeature"},{"id":"T57988","span":{"begin":749,"end":759},"obj":"DiseaseOrPhenotypicFeature"},{"id":"T31365","span":{"begin":260,"end":263},"obj":"DiseaseOrPhenotypicFeature"},{"id":"T48694","span":{"begin":199,"end":205},"obj":"DiseaseOrPhenotypicFeature"},{"id":"T4","span":{"begin":174,"end":177},"obj":"DiseaseOrPhenotypicFeature"},{"id":"T4613","span":{"begin":146,"end":170},"obj":"DiseaseOrPhenotypicFeature"},{"id":"T76063","span":{"begin":100,"end":124},"obj":"DiseaseOrPhenotypicFeature"},{"id":"T80370","span":{"begin":42,"end":52},"obj":"DiseaseOrPhenotypicFeature"},{"id":"T9166","span":{"begin":1551,"end":1556},"obj":"OrganismTaxon"},{"id":"T25701","span":{"begin":1201,"end":1205},"obj":"OrganismTaxon"},{"id":"T51508","span":{"begin":668,"end":672},"obj":"OrganismTaxon"},{"id":"T25854","span":{"begin":622,"end":627},"obj":"OrganismTaxon"},{"id":"T60085","span":{"begin":439,"end":443},"obj":"OrganismTaxon"},{"id":"T30175","span":{"begin":348,"end":353},"obj":"OrganismTaxon"},{"id":"T67382","span":{"begin":273,"end":278},"obj":"OrganismTaxon"},{"id":"T69342","span":{"begin":65,"end":70},"obj":"OrganismTaxon"}],"attributes":[{"id":"A16","pred":"ID:","subj":"T16","obj":"ChemicalEntity"},{"id":"A15","pred":"ID:","subj":"T15","obj":"ChemicalEntity"},{"id":"A14","pred":"ID:","subj":"T14","obj":"ChemicalEntity"},{"id":"A13","pred":"ID:","subj":"T13","obj":"http://purl.obolibrary.org/obo/CHEBI_35143"},{"id":"A12","pred":"ID:","subj":"T12","obj":"ChemicalEntity"},{"id":"A11","pred":"ID:","subj":"T10","obj":"ChemicalEntity"},{"id":"A10","pred":"ID:","subj":"T10","obj":"D017364"},{"id":"A9","pred":"ID:","subj":"T9","obj":"ChemicalEntity"},{"id":"A8","pred":"ID:","subj":"T7","obj":"http://purl.obolibrary.org/obo/CHEBI_10033"},{"id":"A7","pred":"ID:","subj":"T7","obj":"D014859"},{"id":"A6","pred":"ID:","subj":"T6","obj":"ChemicalEntity"},{"id":"A5","pred":"ID:","subj":"T5","obj":"http://purl.obolibrary.org/obo/CHEBI_8583"},{"id":"A4","pred":"ID:","subj":"T3","obj":"http://purl.obolibrary.org/obo/CHEBI_10033"},{"id":"A3","pred":"ID:","subj":"T3","obj":"D014859"},{"id":"A2","pred":"ID:","subj":"T1","obj":"http://purl.obolibrary.org/obo/CHEBI_10033"},{"id":"A1","pred":"ID:","subj":"T1","obj":"D014859"},{"id":"A28925","pred":"#label","subj":"T11","obj":"DISEASE"},{"id":"A4610","pred":"#label","subj":"T24843","obj":"DISEASE"},{"id":"A93653","pred":"#label","subj":"T64851","obj":"D006406"},{"id":"A43651","pred":"#label","subj":"T8","obj":"D006470"},{"id":"A16714","pred":"#label","subj":"T57988","obj":"D006470"},{"id":"A63699","pred":"#label","subj":"T31365","obj":"DISEASE"},{"id":"A63311","pred":"#label","subj":"T48694","obj":"D020521"},{"id":"A4801","pred":"#label","subj":"T4","obj":"DISEASE"},{"id":"A33880","pred":"#label","subj":"T4613","obj":"D002543"},{"id":"A15689","pred":"#label","subj":"T76063","obj":"D002543"},{"id":"A48390","pred":"#label","subj":"T80370","obj":"D006470"}],"text":"Rapid reversal of anticoagulation reduces hemorrhage volume in a mouse model of warfarin-associated intracerebral hemorrhage.\nWarfarin-associated intracerebral hemorrhage (W-ICH) is a severe type of stroke. There is no consensus on the optimal treatment for W-ICH. Using a mouse model, we tested whether the rapid reversal of anticoagulation using human prothrombin complex concentrate (PCC) can reduce hemorrhagic blood volume. Male CD-1 mice were treated with warfarin (2 mg/kg over 24 h), resulting in a mean (+/-s.d.) International Normalized Ratio of 3.5+/-0.9. First, we showed that an intravenous administration of human PCC rapidly reversed anticoagulation in mice. Second, a stereotactic injection of collagenase was administered to induce hemorrhage in the right striatum. Forty-five minutes later, the animals were randomly treated with PCC (100 U/kg) or saline i.v. (n=12 per group). Twenty-four hours after hemorrhage induction, hemorrhagic blood volume was quantified using a photometric hemoglobin assay. The mean hemorrhagic blood volume was reduced in PCC-treated animals (6.5+/-3.1 microL) compared with saline controls (15.3+/-11.2 microL, P=0.015). In the saline group, 45% of the mice developed large hematomas (i.e., \u003e15 microL). In contrast, such extensive lesions were never found in the PCC group. We provide experimental data suggesting PCC to be an effective acute treatment for W-ICH in terms of reducing hemorrhagic blood volume. Future studies are needed to assess the therapeutic potential emerging from our finding for human W-ICH."}

{"project":"PMID_GLOBAL","denotations":[{"id":"T1","span":{"begin":100,"end":124},"obj":"DiseaseOrPhenotypicFeature"},{"id":"T2","span":{"begin":146,"end":170},"obj":"DiseaseOrPhenotypicFeature"},{"id":"T3","span":{"begin":199,"end":205},"obj":"DiseaseOrPhenotypicFeature"},{"id":"T4","span":{"begin":387,"end":390},"obj":"DiseaseOrPhenotypicFeature"},{"id":"T6","span":{"begin":392,"end":395},"obj":"DiseaseOrPhenotypicFeature"},{"id":"T7","span":{"begin":434,"end":436},"obj":"DiseaseOrPhenotypicFeature"},{"id":"T8","span":{"begin":628,"end":631},"obj":"DiseaseOrPhenotypicFeature"},{"id":"T10","span":{"begin":848,"end":851},"obj":"DiseaseOrPhenotypicFeature"},{"id":"T12","span":{"begin":1069,"end":1072},"obj":"DiseaseOrPhenotypicFeature"},{"id":"T14","span":{"begin":1312,"end":1315},"obj":"DiseaseOrPhenotypicFeature"},{"id":"T16","span":{"begin":1363,"end":1366},"obj":"DiseaseOrPhenotypicFeature"}],"attributes":[{"id":"A1","pred":"mondo_id","subj":"T1","obj":"0013792"},{"id":"A2","pred":"mondo_id","subj":"T2","obj":"0013792"},{"id":"A3","pred":"mondo_id","subj":"T3","obj":"0005098"},{"id":"A4","pred":"mondo_id","subj":"T4","obj":"0004974"},{"id":"A5","pred":"mondo_id","subj":"T4","obj":"0022673"},{"id":"A6","pred":"mondo_id","subj":"T6","obj":"0012833"},{"id":"A7","pred":"mondo_id","subj":"T7","obj":"0016063"},{"id":"A8","pred":"mondo_id","subj":"T8","obj":"0004974"},{"id":"A9","pred":"mondo_id","subj":"T8","obj":"0022673"},{"id":"A10","pred":"mondo_id","subj":"T10","obj":"0004974"},{"id":"A11","pred":"mondo_id","subj":"T10","obj":"0022673"},{"id":"A12","pred":"mondo_id","subj":"T12","obj":"0004974"},{"id":"A13","pred":"mondo_id","subj":"T12","obj":"0022673"},{"id":"A14","pred":"mondo_id","subj":"T14","obj":"0004974"},{"id":"A15","pred":"mondo_id","subj":"T14","obj":"0022673"},{"id":"A16","pred":"mondo_id","subj":"T16","obj":"0004974"},{"id":"A17","pred":"mondo_id","subj":"T16","obj":"0022673"}],"text":"Rapid reversal of anticoagulation reduces hemorrhage volume in a mouse model of warfarin-associated intracerebral hemorrhage.\nWarfarin-associated intracerebral hemorrhage (W-ICH) is a severe type of stroke. There is no consensus on the optimal treatment for W-ICH. Using a mouse model, we tested whether the rapid reversal of anticoagulation using human prothrombin complex concentrate (PCC) can reduce hemorrhagic blood volume. Male CD-1 mice were treated with warfarin (2 mg/kg over 24 h), resulting in a mean (+/-s.d.) International Normalized Ratio of 3.5+/-0.9. First, we showed that an intravenous administration of human PCC rapidly reversed anticoagulation in mice. Second, a stereotactic injection of collagenase was administered to induce hemorrhage in the right striatum. Forty-five minutes later, the animals were randomly treated with PCC (100 U/kg) or saline i.v. (n=12 per group). Twenty-four hours after hemorrhage induction, hemorrhagic blood volume was quantified using a photometric hemoglobin assay. The mean hemorrhagic blood volume was reduced in PCC-treated animals (6.5+/-3.1 microL) compared with saline controls (15.3+/-11.2 microL, P=0.015). In the saline group, 45% of the mice developed large hematomas (i.e., \u003e15 microL). In contrast, such extensive lesions were never found in the PCC group. We provide experimental data suggesting PCC to be an effective acute treatment for W-ICH in terms of reducing hemorrhagic blood volume. Future studies are needed to assess the therapeutic potential emerging from our finding for human W-ICH."}